NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癌症單克隆抗體市場:全球行業趨勢、份額、規模、增長、機會、預測(2021-2026)

Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版商 IMARC Services Private Limited 商品編碼 1015492
出版日期 內容資訊 英文 260 Pages
商品交期: 2-3個工作天內
價格
癌症單克隆抗體市場:全球行業趨勢、份額、規模、增長、機會、預測(2021-2026) Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
出版日期: 2021年06月15日內容資訊: 英文 260 Pages
簡介

2015 年至 2020 年,全球癌症單克隆抗體市場規模呈現溫和增長。癌症單克隆抗體是實驗室生成的分子,旨在模擬免疫系統對癌細胞的攻擊。它可以與癌細胞表面存在的抗原結合,標記它們並導致細胞膜破壞,並阻止細胞增殖和免疫系統抑製劑。也可以通過用治療輻射直接照射癌細胞來中和或破壞癌細胞。最常用的單克隆抗體包括用於治療血癌、肝癌、腦癌和乳腺癌的小鼠抗體、嵌合抗體和人源化抗體。

全球癌症患病率的增加是市場增長的主要驅動力之一。與化學療法等傳統非靶向療法相比,單克隆抗體減少了對患者身體的副作用,還可用於治療自身免疫性疾病和炎症性疾病。此外,從業者和腫瘤學家廣泛採用具有成本效益的生物仿製藥單克隆抗體正在推動市場增長。基因測序和靶基因選擇方面的技術進步使這些抗體能夠被修改為具有類似藥物的特性。它們具有相同的效率,但價格低於原藥,有助於使治療更具成本效益,從而促進全球對產品的需求增加。對個性化醫療的日益偏好、廣泛的研發(R&D)活動以及醫療基礎設施的顯著改善也預計將進一步推動市場。 2021 年至 2026 年期間,全球癌症單克隆抗體市場預計將以 4.19% 的複合年增長率增長。

本報告調查了癌症單克隆抗體市場,並按抗體類型、藥物類型、應用、最終用戶、地區和進入市場的公司概況提供了市場概況以及趨勢。我會的。

目錄

第一章前言

第二章範圍和調查方法

第 3 章執行摘要

第 4 章介紹

第 5 章全球癌症單克隆抗體市場

  • 市場概覽
  • 市場表現
  • COVID-19 的影響

第 6 章市場細分,按抗體類型

  • 小鼠抗體
  • 嵌合抗體
  • 人源化抗體
  • 其他

第 7 章市場細分,按藥物類型

  • 貝伐單抗(阿瓦斯汀)
  • 利妥昔單抗(Rituxan)
  • 曲妥珠單抗(赫賽汀)
  • 西妥昔單抗 (Elbitux)
  • 帕尼單抗 (Vectibix)
  • 其他

第 8 章市場細分,按應用

  • 乳腺癌
  • 血癌
  • 肝癌
  • 腦瘤
  • 結直腸癌
  • 其他

第 9 章市場細分,按最終用戶

  • 醫院和診所
  • 藥房
  • 研究所
  • 其他

第 10 章市場細分,按地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 按國家/地區劃分的市場細分

第11章SWOT分析

第十二章價值鏈分析

第十三章波特五力分析

第14章競爭形勢

  • 市場結構
  • 關鍵廠商
  • 關鍵廠商簡介
    • Amgen Inc.
    • Roche Holding AG
    • AbbVie Inc.
    • Johnson & Johnson
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Genmab A/S
    • GlaxoSmithKline Plc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Spectrum Pharmaceuticals Inc.
    • Seattle Genetics Inc.
    • Pfizer Inc.
目錄
Product Code: SR1020D212_Report

The global cancer monoclonal antibodies market exhibited moderate growth during 2015-2020. A cancer monoclonal antibody refers to a laboratory-generated molecule that is engineered to mimic the immune system's attack on cancer cells. It can bind to antigens present on the surface of cancer cells and flag them to trigger the destruction of cell membranes, block cell growth and immune system inhibitors. It can also deliver treatment radiations directly to the cancer cells to neutralize or destroy them. Some of the most commonly used monoclonal antibodies include murine, chimeric and humanized antibodies that are employed in the treatment of cancer in the blood, liver, brain and breast.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient's body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe. Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further. Looking forward, IMARC Group expects the global cancer monoclonal antibodies market to grow at a CAGR of 4.19% during 2021-2026.

Breakup by Antibody Type:

  • Murine Antibodies
  • Chimeric Antibodies
  • Humanized Antibodies
  • Others

Breakup by Medication Type:

  • Bevacizumab (Avastin)
  • Rituximab (Rituxan)
  • Trastuzumab (Herceptin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)
  • Others

Breakup by Application:

  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Others

Breakup by End-User:

  • Hospitals and Clinics
  • Pharmacies
  • Research Laboratories
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

Key Questions Answered in This Report:

  • How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global cancer monoclonal antibodies market?
  • What is the breakup of the market based on the antibody type?
  • What is the breakup of the market based on the medication type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cancer monoclonal antibodies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Monoclonal Antibodies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Antibody Type

  • 6.1 Murine Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Chimeric Antibodies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Humanized Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Medication Type

  • 7.1 Bevacizumab (Avastin)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Rituximab (Rituxan)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Trastuzumab (Herceptin)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cetuximab (Erbitux)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Panitumumab (Vectibix)
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Blood Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Liver Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Brain Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Colorectal Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Research Laboratories
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Others
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Roche Holding AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AbbVie Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Johnson & Johnson
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co., Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Genmab A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 GlaxoSmithKline Plc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Bristol-Myers Squibb Company
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Spectrum Pharmaceuticals Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Seattle Genetics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Pfizer Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Monoclonal Antibodies Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Monoclonal Antibodies Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Cancer Monoclonal Antibodies Market: Breakup by Antibody Type (in %), 2020
  • Figure 4: Global: Cancer Monoclonal Antibodies Market: Breakup by Medication Type (in %), 2020
  • Figure 5: Global: Cancer Monoclonal Antibodies Market: Breakup by Application (in %), 2020
  • Figure 6: Global: Cancer Monoclonal Antibodies Market: Breakup by End-User (in %), 2020
  • Figure 7: Global: Cancer Monoclonal Antibodies Market: Breakup by Region (in %), 2020
  • Figure 8: Global: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 9: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: Cancer Monoclonal Antibodies (Rituximab) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: Cancer Monoclonal Antibodies (Rituximab) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Global: Cancer Monoclonal Antibodies (Cetuximab) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Global: Cancer Monoclonal Antibodies (Cetuximab) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: Global: Cancer Monoclonal Antibodies (Panitumumab) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: Global: Cancer Monoclonal Antibodies (Panitumumab) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: Global: Cancer Monoclonal Antibodies (Other Applications) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: Global: Cancer Monoclonal Antibodies (Other Applications) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: Global: Cancer Monoclonal Antibodies (Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: Global: Cancer Monoclonal Antibodies (Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: Global: Cancer Monoclonal Antibodies (Others) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: Global: Cancer Monoclonal Antibodies (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: North America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: North America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: United States: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: United States: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: Canada: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: Canada: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Asia Pacific: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Asia Pacific: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: China: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: China: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: Japan: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: Japan: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: India: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: India: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: South Korea: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: South Korea: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: Australia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: Australia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 68: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 69: Europe: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 70: Europe: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 71: Germany: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 72: Germany: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 73: France: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 74: France: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 75: United Kingdom: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 76: United Kingdom: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 77: Italy: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 78: Italy: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 79: Spain: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 80: Spain: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 81: Russia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 82: Russia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 83: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 84: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 85: Latin America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 86: Latin America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 87: Brazil: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 88: Brazil: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 89: Mexico: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 90: Mexico: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 91: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 92: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 93: Middle East and Africa: Cancer Monoclonal Antibodies Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 94: Middle East and Africa: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 95: Global: Cancer Monoclonal Antibodies Industry: SWOT Analysis
  • Figure 96: Global: Cancer Monoclonal Antibodies Industry: Value Chain Analysis
  • Figure 97: Global: Cancer Monoclonal Antibodies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Monoclonal Antibodies Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Antibody Type (in Million US$), 2021-2026
  • Table 3: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Medication Type (in Million US$), 2021-2026
  • Table 4: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Application (in Million US$), 2021-2026
  • Table 5: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by End-User (in Million US$), 2021-2026
  • Table 6: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 7: Global: Cancer Monoclonal Antibodies Market: Competitive Structure
  • Table 8: Global: Cancer Monoclonal Antibodies Market: Key Players